{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:27:37Z","timestamp":1792016857490,"version":"4.4.0"},"reference-count":164,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuron"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.neuron.2023.05.017","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T10:46:49Z","timestamp":1686221209000},"page":"2781-2799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":278,"title":["Blood-based biomarkers for Alzheimer\u2019s disease: Current state and future use in a transformed global healthcare landscape"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0894-8982","authenticated-orcid":false,"given":"Harald","family":"Hampel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soeren","family":"Mattke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Iwatsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sid","family":"O\u2019Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie M.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Batrla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vergallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Dage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E.","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuron.2023.05.017_bib1","first-page":"109","article-title":"Defining disease modifying therapy for Alzheimer's disease","volume":"4","author":"Cummings","year":"2017","journal-title":"J.\u00a0Prev. Alzheimers Dis."},{"key":"10.1016\/j.neuron.2023.05.017_bib2","unstructured":"(2023). Highlights of prescribing information: Leqembi (lecanemab-irmb). Eisai Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269s000lbl.pdf"},{"key":"10.1016\/j.neuron.2023.05.017_bib3","unstructured":"(2022). Highlights of prescribing information: Aduhelm (aducanumab-avwa). Biogen. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761178s005lbl.pdf"},{"key":"10.1016\/j.neuron.2023.05.017_bib4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","article-title":"CSF markers for incipient Alzheimer's disease","volume":"2","author":"Blennow","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/j.semnuclmed.2020.12.005","article-title":"Advances in Brain Amyloid Imaging","volume":"51","author":"Krishnadas","year":"2021","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.neuron.2023.05.017_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuron.2023.05.017_bib8","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS\u2013ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.05.017_bib10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib11","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","article-title":"Developing the ATX(N) classification for use across the Alzheimer disease continuum","volume":"17","author":"Hampel","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neurobiolaging.2017.11.009","article-title":"Dysregulation of C-X-C motif ligand 10 during aging and association with cognitive performance","volume":"63","author":"Bradburn","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuron.2023.05.017_bib13","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1093\/brain\/awab332","article-title":"Plasma soluble TREM2 is associated with white matter lesions independent of amyloid and tau","volume":"144","author":"Tsai","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.05.017_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.neurobiolaging.2020.07.009","article-title":"Association of plasma YKL-40 with brain amyloid-\u03b2 levels, memory performance, and sex in subjective memory complainers","volume":"96","author":"Vergallo","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuron.2023.05.017_bib15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12974-019-1531-3","article-title":"Plasma YKL-40 in the spectrum of neurodegenerative dementia","volume":"16","author":"Villar-Piqu\u00e9","year":"2019","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.neuron.2023.05.017_bib16","doi-asserted-by":"crossref","first-page":"e158708","DOI":"10.1172\/JCI158708","article-title":"Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer\u2019s disease","volume":"132","author":"Zhao","year":"2022","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuron.2023.05.017_bib17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","article-title":"Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment","volume":"13","author":"Cicognola","year":"2021","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuron.2023.05.017_bib18","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","article-title":"Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study","volume":"2","author":"Verberk","year":"2021","journal-title":"Lancet. Healthy Longev."},{"key":"10.1016\/j.neuron.2023.05.017_bib19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.4103\/0976-3147.154581","article-title":"Early and late-onset Alzheimer's disease: What are the differences?","volume":"6","author":"Awada","year":"2015","journal-title":"J.\u00a0Neurosci. Rural Pract."},{"key":"10.1016\/j.neuron.2023.05.017_bib20","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.neuron.2023.05.017_bib21","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/alz.12362","article-title":"Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060)","volume":"17","author":"Rajan","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.14283\/jpad.2022.34","article-title":"Aducanumab: Appropriate Use Recommendations Update","volume":"9","author":"Cummings","year":"2022","journal-title":"J.\u00a0Prev. Alzheimers Dis."},{"key":"10.1016\/j.neuron.2023.05.017_bib23","article-title":"Lecanemab: Appropriate Use Recommendations","author":"Cummings","year":"2023","journal-title":"J.\u00a0Prev. Alz. Dis."},{"key":"10.1016\/j.neuron.2023.05.017_bib24","series-title":"Alzheimer's Disease Drug Development: Research and Development Ecosystem","first-page":"345","article-title":"From Trials to Practice: Are We Ready for a Disease-Modifying Treatment","author":"Mattke","year":"2022"},{"key":"10.1016\/j.neuron.2023.05.017_bib25","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrd1130","article-title":"Clinical biomarkers in drug discovery and development","volume":"2","author":"Frank","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuron.2023.05.017_bib26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0197-4580(03)00002-2","article-title":"Biological markers for therapeutic trials in Alzheimer\u2019s disease","volume":"24","author":"Frank","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuron.2023.05.017_bib27","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3115","article-title":"Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives","volume":"9","author":"Hampel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuron.2023.05.017_bib28","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","article-title":"Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic","volume":"14","author":"Hampel","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jalz.2012.05.2116","article-title":"Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian knot","volume":"8","author":"Hampel","year":"2012","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib30","series-title":"Key Barriers to Clinical Trials for Alzheimer's Disease","author":"Malzbender","year":"2020"},{"key":"10.1016\/j.neuron.2023.05.017_bib31","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/alz.12754","article-title":"Using Alzheimer disease blood tests to accelerate clinical trial enrollment","volume":"19","author":"Schindler","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib32","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J.\u00a0Prev. Alzheimers Dis."},{"key":"10.1016\/j.neuron.2023.05.017_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer\u2019s Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuron.2023.05.017_bib34","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuron.2023.05.017_bib36","first-page":"e12081","article-title":"Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: projecting the impact on the cost and wait times","volume":"12","author":"Mattke","year":"2020","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"10.1016\/j.neuron.2023.05.017_bib37","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s43587-022-00269-x","article-title":"Designing the next-generation clinical care pathway for Alzheimer\u2019s disease","volume":"2","author":"Hampel","year":"2022","journal-title":"Nat. Aging"},{"key":"10.1016\/j.neuron.2023.05.017_bib38","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/alz.12470","article-title":"Expected wait times for access to a disease-modifying Alzheimer's treatment in the United States","volume":"18","author":"Mattke","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib39","doi-asserted-by":"crossref","first-page":"e228392","DOI":"10.1001\/jamanetworkopen.2022.8392","article-title":"Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment","volume":"5","author":"Hu","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.neuron.2023.05.017_bib40","unstructured":"FDA. (2022). Evaluation of Elecsys B-Amyloid (1-42) Csf II, Elecsys Phospho-Tau (181p) CSF Decision Summary. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf22\/K221842.pdf"},{"key":"10.1016\/j.neuron.2023.05.017_bib41","first-page":"e12270","article-title":"A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease","volume":"8","author":"Brum","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib42","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum","volume":"79","author":"Jansen","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-021-00430-x","article-title":"Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics","volume":"16","author":"Zetterberg","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuron.2023.05.017_bib44","doi-asserted-by":"crossref","first-page":"e14408","DOI":"10.15252\/emmm.202114408","article-title":"Blood-based biomarkers for Alzheimer's disease","volume":"14","author":"Leuzy","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.neuron.2023.05.017_bib45","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ana.410380413","article-title":"Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease","volume":"38","author":"Motter","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib46","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/sj.mp.4001473","article-title":"Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment","volume":"9","author":"Hampel","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuron.2023.05.017_bib47","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/ana.24454","article-title":"Age and amyloid effects on human central nervous system amyloid-beta kinetics","volume":"78","author":"Patterson","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib48","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","article-title":"CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study","volume":"60","author":"Strozyk","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.05.017_bib49","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-160722","article-title":"Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer's disease","volume":"55","author":"Lewczuk","year":"2017","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuron.2023.05.017_bib50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neuron.2023.05.017_bib51","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status","volume":"76","author":"Palmqvist","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib52","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma beta-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.05.017_bib53","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.25334","article-title":"Plasma amyloid as prescreener for the earliest Alzheimer pathological changes","volume":"84","author":"Verberk","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib54","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib55","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2183\/pjab.90.353","article-title":"Novel plasma biomarker surrogating cerebral amyloid deposition","volume":"90","author":"Kaneko","year":"2014","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.neuron.2023.05.017_bib56","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neulet.2014.04.041","article-title":"The amyloid-\u03b2 degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease","volume":"573","author":"Pannee","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuron.2023.05.017_bib57","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-head comparison of 8 plasma amyloid-beta 42\/40 assays in Alzheimer disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib58","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/brain\/aww015","article-title":"Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography","volume":"139","author":"Palmqvist","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.05.017_bib59","doi-asserted-by":"crossref","first-page":"e12242","DOI":"10.1002\/dad2.12242","article-title":"The global Alzheimer's Association round robin study on plasma amyloid beta methods","volume":"13","author":"Pannee","year":"2021","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"10.1016\/j.neuron.2023.05.017_bib60","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","article-title":"The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review","volume":"14","author":"Brand","year":"2022","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuron.2023.05.017_bib61","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13024-022-00533-z","article-title":"Tauopathies: new perspectives and challenges","volume":"17","author":"Zhang","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuron.2023.05.017_bib62","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02815140","article-title":"Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?","volume":"26","author":"Blennow","year":"1995","journal-title":"Mol. Chem. Neuropathol."},{"key":"10.1016\/j.neuron.2023.05.017_bib63","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","article-title":"Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study","volume":"61","author":"Hampel","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuron.2023.05.017_bib64","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archneur.59.8.1267","article-title":"Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231","volume":"59","author":"Buerger","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib65","doi-asserted-by":"crossref","first-page":"e20200861","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease","volume":"217","author":"Barth\u00e9lemy","year":"2020","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.neuron.2023.05.017_bib66","doi-asserted-by":"crossref","first-page":"eabl8809","DOI":"10.1126\/sciadv.abl8809","article-title":"Alzheimer\u2019s disease: Ablating single master site abolishes tau hyperphosphorylation","volume":"8","author":"Stefanoska","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.neuron.2023.05.017_bib67","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease","volume":"26","author":"Barth\u00e9lemy","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2023.05.017_bib68","doi-asserted-by":"crossref","first-page":"103836","DOI":"10.1016\/j.ebiom.2022.103836","article-title":"Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease","volume":"76","author":"Ashton","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neuron.2023.05.017_bib69","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/brain\/awaa399","article-title":"Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum","volume":"144","author":"Moscoso","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.05.017_bib70","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease","volume":"143","author":"Mattsson-Carlgren","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.05.017_bib71","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","article-title":"Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib72","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: A new biomarker for incipient Alzheimer's disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.05.017_bib73","doi-asserted-by":"crossref","first-page":"103837","DOI":"10.1016\/j.ebiom.2022.103837","article-title":"Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET","volume":"76","author":"Tissot","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neuron.2023.05.017_bib74","doi-asserted-by":"crossref","first-page":"e12921","DOI":"10.15252\/emmm.202012921","article-title":"Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A\u03b2 pathology are detected","volume":"12","author":"Su\u00e1rez-Calvet","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.neuron.2023.05.017_bib75","first-page":"1797","article-title":"Plasma p-tau231 and p-tau217 as state\u00a0markers of amyloid-beta pathology in preclinical Alzheimer's disease","volume":"28","author":"Mil\u00e0-Alom\u00e0","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2023.05.017_bib76","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib77","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer's disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2023.05.017_bib78","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib79","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13024-022-00578-0","article-title":"Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels","volume":"17","author":"Murray","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuron.2023.05.017_bib80","doi-asserted-by":"crossref","DOI":"10.1002\/alz.064277","article-title":"Tau phosphorylation is more closely associated with amyloid-\u03b2 plaques than with tau neurofibrillary tangles","volume":"18","author":"Vermeiren","year":"2022","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuron.2023.05.017_bib81","doi-asserted-by":"crossref","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","article-title":"A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease","volume":"6","author":"Mattsson-Carlgren","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.neuron.2023.05.017_bib82","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","article-title":"Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes","volume":"77","author":"Fleisher","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib83","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00401-021-02400-5","article-title":"CSF p-tau increase in response to Abeta-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles","volume":"143","author":"Kaeser","year":"2022","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.05.017_bib84","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","article-title":"Tau Kinetics in Neurons and the Human Central Nervous System","volume":"97","author":"Sato","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.neuron.2023.05.017_bib85","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","article-title":"Blood phospho-tau in Alzheimer disease: Analysis, interpretation, and clinical utility","volume":"18","author":"Karikari","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib86","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib87","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","article-title":"Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease","volume":"11","author":"Janelidze","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuron.2023.05.017_bib88","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2023.05.017_bib89","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","article-title":"Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231","volume":"13","author":"Bayoumy","year":"2021","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuron.2023.05.017_bib90","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","article-title":"Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes","volume":"78","author":"Mielke","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib91","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.neuron.2023.05.017_bib92","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1083\/jcb.74.1.241","article-title":"Immunofluorescence studies of neurofilaments in the rat and human peripheral and central nervous system","volume":"74","author":"Schlaepfer","year":"1977","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.neuron.2023.05.017_bib93","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1046\/j.1471-4159.1996.67052013.x","article-title":"Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF","volume":"67","author":"Rosengren","year":"1996","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuron.2023.05.017_bib94","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","article-title":"Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression","volume":"73","author":"Zetterberg","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib95","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib96","doi-asserted-by":"crossref","first-page":"120380","DOI":"10.1016\/j.jns.2022.120380","article-title":"Neurofilaments in neurologic disorders and beyond","volume":"441","author":"Mak","year":"2022","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.neuron.2023.05.017_bib97","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences Between Plasma and Cerebrospinal Fluid Glial\u00a0Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib98","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease","volume":"11","author":"Chatterjee","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuron.2023.05.017_bib99","series-title":"Siemens Healthineers Receives FDA Breakthrough Device Designation for sNfL test in Multiple Sclerosis","year":"2022"},{"key":"10.1016\/j.neuron.2023.05.017_bib100","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/alz.12301","article-title":"Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study","volume":"17","author":"Brickman","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib101","first-page":"434","article-title":"Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70","volume":"144","author":"Keshavan","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.05.017_bib102","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13195-021-00942-0","article-title":"The accuracy and robustness of plasma biomarker models for amyloid PET positivity","volume":"14","author":"Benedet","year":"2022","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuron.2023.05.017_bib103","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","article-title":"Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative","volume":"26","author":"Karikari","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuron.2023.05.017_bib104","doi-asserted-by":"crossref","first-page":"fcab008","DOI":"10.1093\/braincomms\/fcab008","article-title":"Detection of beta-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers","volume":"3","author":"Tosun","year":"2021","journal-title":"Brain Commun."},{"key":"10.1016\/j.neuron.2023.05.017_bib105","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2023.05.017_bib106","doi-asserted-by":"crossref","DOI":"10.1002\/alz.13026","article-title":"Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease","author":"Therriault","year":"2023","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuron.2023.05.017_bib107","doi-asserted-by":"crossref","first-page":"e1681","DOI":"10.1212\/WNL.0000000000012727","article-title":"Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 assays","volume":"97","author":"Leuzy","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.05.017_bib108","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13195-020-00596-4","article-title":"Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification","volume":"12","author":"Barth\u00e9lemy","year":"2020","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuron.2023.05.017_bib109","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neuron.2023.05.017_bib110","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.05.017_bib111","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jnc.13600","article-title":"Tau physiology and pathomechanisms in frontotemporal lobar degeneration","volume":"138","author":"Bodea","year":"2016","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuron.2023.05.017_bib112","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/jnnp-2020-323487","article-title":"Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration","volume":"91","author":"Benussi","year":"2020","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuron.2023.05.017_bib113","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/brain\/awac407","article-title":"Brain-derived tau: A novel blood-based biomarker for Alzheimer's disease-type neurodegeneration","volume":"146","author":"Gonzalez-Ortiz","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.05.017_bib114","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/alz.12395","article-title":"Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Abeta42\/Abeta40 and p-tau","volume":"18","author":"Janelidze","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib115","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/alz.12751","article-title":"An accurate fully automated panel of plasma biomarkers for Alzheimer's disease","volume":"19","author":"Palmqvist","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib116","doi-asserted-by":"crossref","first-page":"689938","DOI":"10.3389\/fnins.2021.689938","article-title":"Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies","volume":"15","author":"Yuan","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuron.2023.05.017_bib117","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13195-020-00682-7","article-title":"Combination of plasma amyloid beta((1-42\/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology","volume":"12","author":"Verberk","year":"2020","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuron.2023.05.017_bib118","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease","volume":"17","author":"Simr\u00e9n","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib119","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/alz.12447","article-title":"Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease","volume":"18","author":"Chatterjee","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3233\/JAD-200755","article-title":"Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease Stage","volume":"78","author":"Asken","year":"2020","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuron.2023.05.017_bib121","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3233\/JAD-180325","article-title":"Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer\u2019s Disease and Correlates with Cognitive Impairment","volume":"67","author":"Oeckl","year":"2019","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuron.2023.05.017_bib122","unstructured":"(2022). Evaluation of Automatic Class III Designation for Lumipulse G 13-Amyloid Ratio (1-42\/1-40) Decision Summary. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/DEN200072.pdf"},{"key":"10.1016\/j.neuron.2023.05.017_bib123","first-page":"1027","article-title":"[18F]-AV1451 Autoradiography Signal Correlates with Anti-pathological Tau IHC Signal in AD Post-Mortem Cortical Tissue Sections","volume":"57","author":"Liang","year":"2016","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.neuron.2023.05.017_bib124","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","article-title":"Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline","volume":"140","author":"Lantero Rodriguez","year":"2020","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuron.2023.05.017_bib125","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1093\/brain\/awac175","article-title":"Ante-mortem plasma phosphorylated tau (181) predicts Alzheimer's disease neuropathology and regional tau at autopsy","volume":"145","author":"Morrison","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.neuron.2023.05.017_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib127","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s00259-020-04942-4","article-title":"Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: An [(18)F] flutemetamol amyloid PET study","volume":"48","author":"Hanseeuw","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.neuron.2023.05.017_bib128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","article-title":"Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers","volume":"11","author":"Salvad\u00f3","year":"2019","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuron.2023.05.017_bib129","doi-asserted-by":"crossref","first-page":"68","DOI":"10.14283\/jpad.2020.51","article-title":"Comparative analysis of different definitions of amyloid-beta positivity to detect early downstream pathophysiological alterations in preclinical Alzheimer","volume":"8","author":"Mil\u00e0-Alom\u00e0","year":"2021","journal-title":"J.\u00a0Prev. Alzheimers Dis."},{"key":"10.1016\/j.neuron.2023.05.017_bib130","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","article-title":"Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations","volume":"12","author":"Cullen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuron.2023.05.017_bib131","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","article-title":"Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations","volume":"1","author":"Cullen","year":"2021","journal-title":"Nat. Aging"},{"key":"10.1016\/j.neuron.2023.05.017_bib132","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","article-title":"Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers","volume":"80","author":"Mattsson-Carlgren","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib133","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","article-title":"Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures","volume":"27","author":"Palmqvist","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2023.05.017_bib134","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of Abeta42\/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring","volume":"28","author":"Ashton","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuron.2023.05.017_bib135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.tins.2022.12.004","article-title":"The foundation and architecture of precision medicine in neurology and psychiatry","volume":"46","author":"Hampel","year":"2023","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuron.2023.05.017_bib136","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/alz.12801","article-title":"Clinical performance and robustness evaluation of plasma amyloid-beta42\/40 prescreening","volume":"19","author":"Rabe","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib137","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/alz.12706","article-title":"Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models","volume":"19","author":"Cullen","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib138","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/alz.12647","article-title":"Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice","volume":"19","author":"O'Bryant","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib139","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jamaneurol.2022.0976","article-title":"Risk factors associated with Alzheimer disease and related dementias by sex and race and ethnicity in the US","volume":"79","author":"Nianogo","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib140","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/alz.12466","article-title":"Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities","volume":"18","author":"Syrjanen","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib141","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/alz.12759","article-title":"Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease","volume":"19","author":"Depypere","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib142","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","article-title":"Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios","volume":"80","author":"Janelidze","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib143","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1212\/WNL.0000000000200358","article-title":"Effect of race on prediction of brain amyloidosis by plasma Abeta42\/Abeta40, phosphorylated tau, and neurofilament light","volume":"99","author":"Schindler","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.05.017_bib144","doi-asserted-by":"crossref","first-page":"e12315","DOI":"10.1002\/dad2.12315","article-title":"Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI","volume":"14","author":"Windon","year":"2022","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"10.1016\/j.neuron.2023.05.017_bib145","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: A retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib146","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib147","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","article-title":"Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers","volume":"16","author":"Frisoni","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cca.2021.05.011","article-title":"The PrecivityAD test: Accurate and reliable LC-MS\/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis","volume":"519","author":"Kirmess","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.neuron.2023.05.017_bib151","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/acn3.51763","article-title":"Independent study demonstrates amyloid probability score accurately indicates amyloid pathology","volume":"10","author":"Fogelman","year":"2023","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neuron.2023.05.017_bib152","series-title":"C\u2082N Diagnostics receives breakthrough device designation from U.S. FDA for blood test to screen for Alzheimer\u2019s disease risk","year":"2019"},{"key":"10.1016\/j.neuron.2023.05.017_bib153","doi-asserted-by":"crossref","first-page":"34","DOI":"10.14283\/jpad.2018.41","article-title":"Plasma Abeta42\/40 ratio detects early stages of Alzheimer's disease and correlates with CSF and neuroimaging biomarkers in the AB255 study","volume":"6","author":"P\u00e9rez-Grijalba","year":"2019","journal-title":"J.\u00a0Prev. Alzheimers Dis."},{"key":"10.1016\/j.neuron.2023.05.017_bib154","doi-asserted-by":"crossref","first-page":"e1580","DOI":"10.1212\/WNL.0000000000009240","article-title":"Total A\u03b2(42)\/A\u03b2(40) ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis","volume":"94","author":"Doecke","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neuron.2023.05.017_bib155","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13195-021-00911-7","article-title":"Performance of the plasma Abeta42\/Abeta40 ratio, measured with a novel HPLC-MS\/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort","volume":"13","author":"Jang","year":"2021","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuron.2023.05.017_bib156","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13195-016-0225-7","article-title":"A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-\u03b2 1\u201342 peptide in human plasma with utility for studies of Alzheimer\u2019s disease therapeutics","volume":"8","author":"Song","year":"2016","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuron.2023.05.017_bib157","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/alz.12697","article-title":"Comparative analytical performance of multiple plasma Abeta42 and Abeta40 assays and their ability to predict positron emission tomography amyloid positivity","volume":"19","author":"Zicha","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuron.2023.05.017_bib158","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbrc.2021.08.066","article-title":"Fully automated chemiluminescence enzyme immunoassays showing high correlation with immunoprecipitation mass spectrometry assays for beta-amyloid (1-40) and (1-42) in plasma samples","volume":"576","author":"Yamashita","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuron.2023.05.017_bib159","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13195-022-01029-0","article-title":"Fully automated and highly specific plasma \u03b2-amyloid immunoassays predict \u03b2-amyloid status defined by amyloid positron emission tomography with high accuracy","volume":"14","author":"Yamashita","year":"2022","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuron.2023.05.017_bib160","series-title":"Roche's Elecsys Amyloid Plasma Panel granted FDA Breakthrough Device Designation to enable a timely diagnosis of Alzheimer\u2019s disease","year":"2022"},{"key":"10.1016\/j.neuron.2023.05.017_bib161","series-title":"Quanterix launches first PTau-181 plasma laboratory developed test for clinical diagnostic and research applications in the U.S.","year":"2022"},{"key":"10.1016\/j.neuron.2023.05.017_bib162","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13195-022-01005-8","article-title":"Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217","volume":"14","author":"Groot","year":"2022","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.neuron.2023.05.017_bib163","doi-asserted-by":"crossref","first-page":"e12204","DOI":"10.1002\/dad2.12204","article-title":"Development and validation of a high-sensitivity assay for measuring p217+tau in plasma","volume":"13","author":"Triana-Baltzer","year":"2021","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"10.1016\/j.neuron.2023.05.017_bib164","doi-asserted-by":"crossref","first-page":"e12307","DOI":"10.1002\/dad2.12307","article-title":"Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum","volume":"14","author":"Dore","year":"2022","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"10.1016\/j.neuron.2023.05.017_bib148","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2016.05.014","article-title":"CSF A\u03b2(1-42) - an excellent but complicated Alzheimer's biomarker - a route to standardisation","volume":"467","author":"Kuhlmann","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.neuron.2023.05.017_bib149","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/alz.12145","article-title":"First amyloid \u03b21-42 certified reference material for re-calibrating commercial immunoassays","volume":"16","author":"Boulo","year":"2020","journal-title":"Alzheimers Dement."}],"container-title":["Neuron"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896627323003902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896627323003902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T07:45:02Z","timestamp":1760255102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896627323003902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":164,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0896627323003902"],"URL":"https:\/\/doi.org\/10.1016\/j.neuron.2023.05.017","relation":{},"ISSN":["0896-6273"],"issn-type":[{"value":"0896-6273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood-based biomarkers for Alzheimer\u2019s disease: Current state and future use in a transformed global healthcare landscape","name":"articletitle","label":"Article Title"},{"value":"Neuron","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuron.2023.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}